Lizaida Perez
FDA investigator
Appears on 2 documents from 2024 to 2026, mostly at sites in California. Most often cites postmarketing reporting of adverse experiences (21 CFR 600.80).
- 2
- Documents on file
- 5.0
- Observations per 483
- 2024
- First seen
- 2026
- Most recent
What they cite most
From 10 observations- 21 CFR 600.80Postmarketing reporting of adverse experiences1
Activity by year
2024: 1, 2026: 1
Where
California 1 · Maryland 1
Often inspects with
Is Lizaida Perez coming to your site?
Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.
Ask about any investigator in Claude or ChatGPT with the AI connector.
Inspection history
2 documents, newest first| Date | Firm | Location | Observations | Open |
|---|---|---|---|---|
| 2026-03-25 | 483 Dendreon Pharmaceuticals LLCMar 25, 2026 · Seal Beach, California | Seal Beach, California | 9 | |
| 2024-11-01 | 483 Form FDA 483 Kite Pharma November 2024Nov 1, 2024 · Frederi ck, Maryland | Frederi ck, Maryland | 1 |
About this profile
What does Lizaida Perez inspect?
Lizaida Perez appears on 2 documents on file covering 1 site, mostly in California.
What do they cite most often?
21 CFR 600.80 (postmarketing reporting of adverse experiences).
Can I read the observations?
Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.
How current is this profile?
The most recent document on file for Lizaida Perez is dated Mar 25, 2026.